Reuters: Two experimental Ebola vaccines pass safety test in African trial
“Two experimental Ebola vaccines, one from GlaxoSmithKline PLC and the other from biotech start-up NewLink Genetics Corp, ‘appear to be safe’ part way through a clinical trial being conducted in Liberia, the U.S. National Institutes of Health (NIH) said on Thursday…” (Begley, 3/26).

Wall Street Journal: Two Experimental Ebola Vaccines Appear to Be Safe in Trial
“…The safety goals for the vaccines have been met, but proving that they are effective — the next step in the research — now appears to be a more complicated project than originally envisioned. Investigators had planned to enroll 27,000 people in Liberia at a high risk of developing Ebola, such as health care workers…” (Burton, 3/26).